Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA therapeutics against 2019-nCoV
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
siRNA therapeutics against 2019-nCoV is an early Sirnaomics research program to develop **small interfering RNA** agents for prophylaxis and treatment of severe acute respiratory infection caused by SARS-CoV-2. The concept uses sequence-specific RNA interference to silence essential viral genes required for infection and replication, with respiratory-targeted formulation intended for local delivery to the airways via a handheld nebulizer. Based on the available information, this effort remained a preclinical discovery program with multiple unnamed siRNA candidates rather than a single disclosed drug product, and no specific active siRNA sequence, brand name, or approved therapeutic emerged from the program.
- Other names
- siRNA therapeutics against 2019-nCoVRNAi-based prophylactics and therapeutics for 2019-nCoVsiRNA therapeutics against SARS-CoV-2
02
Targets
SARS-CoV-2 RNA
Beyond the preview
Go deeper on siRNA therapeutics against 2019-nCoV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA therapeutics against 2019-nCoV.